Header Logo

Connection

ELIZABETH SHPALL to Idarubicin

Back to Details
This is a "connection" page, showing publications ELIZABETH SHPALL has written about Idarubicin.
ELIZABETH SHPALL
Connection Strength
0.189
Idarubicin
  1. Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia. Am J Hematol. 2023 11; 98(11):1711-1720.
    View in: PubMed
    Score: 0.189
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.